30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Reimbursement / Regulatory

NuVasive Receives Regulatory Clearances for Bone Transport System -

NuVasive received FDA 510(k) clearance and CE Mark approval to market Precice® Bone Transport, an all-internal treatment for segmental bone loss in the tibia and femur resulting from trauma or infection. The system is slated for 3Q19 launch in the U.S. and Europe. It includes an implantable, magnetic stainless steel intramedullary nail with a dual slot designed to support the transport of an intercalary bone segment to facilitate regeneration in bone defects. An external remote controller moves the bone segment up to 10 centimeters. (NuVasive, Inc., 2/19/19)